You are here


Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small molecule oncolytic immunotherapy PV-10 for the treatment of ocular melanoma (to include all melanoma disease affecting the eye and orbit). Intratumoral injection of small molecule oncolytic immunotherapy PV-10 can yield immunogenic cell death (ICD) in solid tumor cancers and stimulate tumor-specific reactivity in circulating T cells.1-4

Whats the big deal???? Well this is the first time that we here in Ireland know of that they have injected tumors in the liver with PV-10. Before it was impossible to get deep tissue injecting. Have a look at their study paper here. One point of interest is the observation of central necrosis in one particular liver tumor. This is the tumor dying from its centre out. Which is different to it dying at its edges. We think this has WAY more potential to have successful outcomes.

We will follow, track & report on this development with much interest.

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer